Citius Oncology (CTOR) Common Equity (2022 - 2026)
Citius Oncology (CTOR) posted quarterly Common Equity of $35.3 million for Q1 2026, down 1.05% year-over-year from $35.6 million in Q1 2025, and down 39.62% quarter-over-quarter from $58.4 million in Q4 2025.
Citius Oncology (CTOR) Common Equity (2022 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Common Equity for 5 consecutive years, with $35.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 1.05% year-over-year to $35.3 million; the TTM figure through Mar 2026 stood at $35.3 million (down 1.05% YoY), while the FY2025 annual figure was $44.9 million, down 2.76% from the prior year.
- Common Equity fell to $35.3 million in Q1 2026 per CTOR's latest filing, from $58.4 million in the prior quarter.
- Across five years, Common Equity topped out at $58.4 million in Q4 2025 and bottomed at -$1968.0 in Q2 2023.
- Historically, Common Equity has averaged $27.1 million across 5 years, with a median of $29.0 million in 2023.
- Annual changes were most pronounced in 2024 — Common Equity jumped 865489.28% — and 2025, when it retreated 2.76%.
- Citius Oncology's Common Equity stood at $345508.0 in 2022, then soared by 6477.35% to $22.7 million in 2023, then surged by 81.69% to $41.3 million in 2024, then surged by 41.47% to $58.4 million in 2025, then plunged by 39.62% to $35.3 million in 2026.
- Business Quant data shows CTOR's Common Equity at $35.3 million in Q1 2026, $58.4 million in Q4 2025, and $44.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn | 40.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.27 Mn |
| Dec 31, 2025 | 58.41 Mn |
| Sep 30, 2025 | 44.87 Mn |
| Jun 30, 2025 | 32.40 Mn |
| Mar 31, 2025 | 35.64 Mn |
| Dec 31, 2024 | 41.29 Mn |
| Sep 30, 2024 | 46.14 Mn |
| Jun 30, 2024 | 17.03 Mn |
| Mar 31, 2024 | 19.85 Mn |
| Dec 31, 2023 | 22.73 Mn |
| Sep 30, 2023 | 25.54 Mn |
| Jun 30, 2023 | -1,968.00 |
| Mar 31, 2023 | 197,586.00 |
| Dec 31, 2022 | 345,508.00 |